UC Irvine-led study found that exposure to previously unknown PFAS chemicals was associated with a higher risk of acute lymphoblastic leukemia, the most common childhood cancer. Read more: https://news.uci.edu/2026/04/27/forever-chemicals-may-be-linked-to-childhood-leukemia/

In multiple models of Ewing sarcoma—a rare and aggressive cancer affecting children and young adults—the treatment eliminated established tumors and dramatically reduced the spread of cancer. Read more: https://medicalxpress.com/news/2026-04-therapy-aggressive-childhood-adult-cancers.html

Efforts to develop effective therapies for MYC-amplified Group 3 medulloblastoma (G3-MB) are hindered by an incomplete understanding of how MYC expression is controlled in these tumors. Read more: https://www.eurekalert.org/news-releases/1125370

Researchers at Linköping University show how two important cancer-related proteins can be prevented from collaborating with each other. The discovery shows the way toward future medications to combat, for example, neuroblastoma in children. Read more: https://medicalxpress.com/news/2026-04-scientists-undruggable-childhood-cancer-protein.html

A new clinical trial led by the Penn State College of Medicine–based Beat Childhood Cancer Research Consortium will evaluate whether the drug eflornithine (DFMO) can help prevent relapse and improve outcomes for patients with Ewing sarcoma and osteosarcoma — two aggressive bone cancers that have seen few meaningful treatment advances in decades, according to Giselle Saulnier Sholler, MD, MSc, chair and founder of the consortium. Read more: https://pennstatehealthnews.org/2026

Now, Cincinnati Children’s is working with New Zealand-based BioOra, Ltd, to launch a clinical trial that would bring a lower-risk, “third-generation” CAR-T therapy—called Alta-cel—to children and teens with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Read more: https://scienceblog.cincinnatichildrens.org/clinical-trial-to-evaluate-safer-car-t-cell-therapy-for-children/

Most people diagnosed with pediatric cancer are living longer than ever, but many face unique challenges as adults – and not all of them are physical. Read more: https://news.cuanschutz.edu/cancer-center/overholser-pediatric-cancer-survivorship

B-cell acute lymphoblastic leukaemia is the most common form of childhood cancer. In this type of cancer, which affects blood cells, one of the most common abnormalities is the presence of cells with an excess of chromosomes (hyperdiploidy), a condition that leads to chromosomal instability. Now, a study published in Cell Reports reveals that this chromosomal instability caused by hyperdiploidy reduces the proliferation of the affected cells, delays their differentiation an

The field of pediatric oncofertility focuses on efforts to protect and preserve a patient’s fertility potential and reproductive hormone function from the effects of cancer treatments like chemotherapy and radiation — two considerations known to be extremely important for overall health and well-being. Read more: https://news.cuanschutz.edu/accords/beyond-survival-the-push-to-protect-future-fertility-for-pediatric-patients-with-cancer

Diagnosed with DIPG at age six, Lucas’ doctor Jacques Grill told Lucas’ parents, Cedric and Olesja, that he was unlikely to live very long. Instead of giving up hope, Cedric and Olesja flew Lucas to France to participate in a clinical trial called BIOMEDE, which tested new potential drugs against DIPG. Read more: https://www.upworthy.com/first-person-cured-of-dipg-ex1/